Indication

Afibrinogenemia

Afibrinogenemia is a rare, severe hematologic disorder characterized by the complete absence or undetectable levels of circulating fibrinogen (coagulation factor I) in the blood. Read more about Afibrinogenemia

4 drugs 4 manufacturers

Advertisement

Drugs that treat it

Common Afibrinogenemia therapies.

Showing 1–4 of 4 drugs

Filter & compare in the drug finder →Opens the drug finder with Afibrinogenemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Afibrinogenemia.

Afibrinogenemia is a rare, severe hematologic disorder characterized by the complete absence or undetectable levels of circulating fibrinogen (coagulation factor I) in the blood.

Typically inherited in an autosomal recessive pattern due to mutations in the fibrinogen gene cluster (*FGA*, *FGB*, or *FGG*), it can also rarely be acquired secondary to severe hepatic failure or hyperconsumptive states.

Pathophysiologically, the absence of fibrinogen impairs both stable fibrin clot formation and normal platelet aggregation, disrupting primary and secondary hemostasis.

Clinically, affected individuals experience a lifelong bleeding diathesis that frequently presents in the neonatal period with prolonged umbilical cord hemorrhage, followed by mucosal bleeding, hemarthroses, hematomas, and potentially fatal spontaneous intracranial hemorrhage, paradoxical thromboembolism, or recurrent early pregnancy loss.

Personalize your experience

Follow Afibrinogenemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it